Report Overview

The EU Liver Disease Treatment market size stood at round USD $2.08 billion in 2019 and is projected to reach USD $3.62 billion by 2028, exhibiting a CAGR of xx% during the forecast period

The liver is a vital organ of the body performing umpteen complex functions such as fighting infections, removing toxins, bile secretion, and it produces clotting factors,
proteins, and cholesterol, among others. Malfunctioning of the liver can be life threatening. It can cause multiple acute and chronic diseases (hepatitis, non-alcoholic fatty liver disease, liver cancer, liver tumor, and liver cirrhosis). The initial liver damage symptoms include nausea, fatigue, diarrhea, jaundice, swollen abdomen, and mental disorientation, among others. Acute liver damage can be treated through proper
medication if detected early. Otherwise, a liver transplant is required. Liver damage can be prevented by adopting a healthy lifestyle and practicing proper hygiene



Market Drivers

The percentage of the aged population diagnosing with liver-related diseases is significantly increasing in Europe and is primarily driving the growth of the European liver
disease treatment market. Europe is among one of the leading markets for Liver Disease Treatment Drugs. As per a report, liver cirrhosis causes 170,000 deaths in Europe
annually. Within Europe, Germany, France, and the United Kingdom account for the largest liver disease treatment market share

Various technological advancements in the imaging techniques, Y-O-Y increase in the patients diagnosing with the liver diseases further contribute to the growth of the market. The increasing number of mergers and acquisitions that are happening between the companies is predicted to shape the face of the market better during the forecast period. The license expiration of a few drugs and robust pipeline drugs for the treatment of liver diseases is adding fuel to the market